Inhibitory effects of β-adrenergic agonists on gastric acid secretion in dogs

M. H. Stevens, R. C. Thirlby, C. T. Richardson, M. A. Fredrickson, R. H. Unger, M. Feldman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We evaluated the effect of two β-adrenergic agonists, isoproterenol (nonselective agonist) and terbutaline (selective β2-agonist), on gastric acid secretion stimulated by intravenous pentagastrin, bethanechol, or histamine in dogs with gastric fistulas. Intravenous infusion of isoproterenol or terbutaline inhibited pentagastrin-stimulated acid secretion to a significantly greater extent than they inhibited bethanechol- or histamine-stimulated acid secretion. For example, isoproterenol (12 μg.kg-1.h-1) reduced mean pentagastrin-, bethanechol-, and histamine-stimulated acid output by 86, 63, and 14%, respectively. Percent inhibition of acid secretion with terbutaline (30 μg.kg-1.h-1) averaged 60, 17, and 24% for pentagastrin, bethanechol, and histamine, respectively. Terbutaline also inhibited pentagastrin-stimulated acid secretion from vagally denervated fundic pouches in a dose-related manner. Plasma somatostatin-like immunoreactivity was significantly higher during infusion of terbutaline plus pentagastrin than during infusion of pentagastrin alone. However, an intravenous infusion of 0.3 μg.kg-1.h-1 somatostatin-14 had no effect on pentagastrin-stimulated acid secretion from the gastric fistula, even though this infusion increased plasma somatostatin-like immunoreactivity to the same extent as terbutaline plus pentagastrin infusion. Thus the amount of somatostatin released during terbutaline infusion was not sufficient to explain the inhibition of pentagastrin-stimulated acid secretion observed.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume251
Issue number4
StatePublished - 1986

Fingerprint

Pentagastrin
Adrenergic Agonists
Gastric Acid
Terbutaline
Dogs
Bethanechol
Acids
Histamine
Isoproterenol
Gastric Fistula
Somatostatin
Intravenous Infusions

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Inhibitory effects of β-adrenergic agonists on gastric acid secretion in dogs. / Stevens, M. H.; Thirlby, R. C.; Richardson, C. T.; Fredrickson, M. A.; Unger, R. H.; Feldman, M.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 251, No. 4, 1986.

Research output: Contribution to journalArticle

Stevens, M. H. ; Thirlby, R. C. ; Richardson, C. T. ; Fredrickson, M. A. ; Unger, R. H. ; Feldman, M. / Inhibitory effects of β-adrenergic agonists on gastric acid secretion in dogs. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 1986 ; Vol. 251, No. 4.
@article{2456aa5956fe40fea3aa2918095f6953,
title = "Inhibitory effects of β-adrenergic agonists on gastric acid secretion in dogs",
abstract = "We evaluated the effect of two β-adrenergic agonists, isoproterenol (nonselective agonist) and terbutaline (selective β2-agonist), on gastric acid secretion stimulated by intravenous pentagastrin, bethanechol, or histamine in dogs with gastric fistulas. Intravenous infusion of isoproterenol or terbutaline inhibited pentagastrin-stimulated acid secretion to a significantly greater extent than they inhibited bethanechol- or histamine-stimulated acid secretion. For example, isoproterenol (12 μg.kg-1.h-1) reduced mean pentagastrin-, bethanechol-, and histamine-stimulated acid output by 86, 63, and 14{\%}, respectively. Percent inhibition of acid secretion with terbutaline (30 μg.kg-1.h-1) averaged 60, 17, and 24{\%} for pentagastrin, bethanechol, and histamine, respectively. Terbutaline also inhibited pentagastrin-stimulated acid secretion from vagally denervated fundic pouches in a dose-related manner. Plasma somatostatin-like immunoreactivity was significantly higher during infusion of terbutaline plus pentagastrin than during infusion of pentagastrin alone. However, an intravenous infusion of 0.3 μg.kg-1.h-1 somatostatin-14 had no effect on pentagastrin-stimulated acid secretion from the gastric fistula, even though this infusion increased plasma somatostatin-like immunoreactivity to the same extent as terbutaline plus pentagastrin infusion. Thus the amount of somatostatin released during terbutaline infusion was not sufficient to explain the inhibition of pentagastrin-stimulated acid secretion observed.",
author = "Stevens, {M. H.} and Thirlby, {R. C.} and Richardson, {C. T.} and Fredrickson, {M. A.} and Unger, {R. H.} and M. Feldman",
year = "1986",
language = "English (US)",
volume = "251",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Inhibitory effects of β-adrenergic agonists on gastric acid secretion in dogs

AU - Stevens, M. H.

AU - Thirlby, R. C.

AU - Richardson, C. T.

AU - Fredrickson, M. A.

AU - Unger, R. H.

AU - Feldman, M.

PY - 1986

Y1 - 1986

N2 - We evaluated the effect of two β-adrenergic agonists, isoproterenol (nonselective agonist) and terbutaline (selective β2-agonist), on gastric acid secretion stimulated by intravenous pentagastrin, bethanechol, or histamine in dogs with gastric fistulas. Intravenous infusion of isoproterenol or terbutaline inhibited pentagastrin-stimulated acid secretion to a significantly greater extent than they inhibited bethanechol- or histamine-stimulated acid secretion. For example, isoproterenol (12 μg.kg-1.h-1) reduced mean pentagastrin-, bethanechol-, and histamine-stimulated acid output by 86, 63, and 14%, respectively. Percent inhibition of acid secretion with terbutaline (30 μg.kg-1.h-1) averaged 60, 17, and 24% for pentagastrin, bethanechol, and histamine, respectively. Terbutaline also inhibited pentagastrin-stimulated acid secretion from vagally denervated fundic pouches in a dose-related manner. Plasma somatostatin-like immunoreactivity was significantly higher during infusion of terbutaline plus pentagastrin than during infusion of pentagastrin alone. However, an intravenous infusion of 0.3 μg.kg-1.h-1 somatostatin-14 had no effect on pentagastrin-stimulated acid secretion from the gastric fistula, even though this infusion increased plasma somatostatin-like immunoreactivity to the same extent as terbutaline plus pentagastrin infusion. Thus the amount of somatostatin released during terbutaline infusion was not sufficient to explain the inhibition of pentagastrin-stimulated acid secretion observed.

AB - We evaluated the effect of two β-adrenergic agonists, isoproterenol (nonselective agonist) and terbutaline (selective β2-agonist), on gastric acid secretion stimulated by intravenous pentagastrin, bethanechol, or histamine in dogs with gastric fistulas. Intravenous infusion of isoproterenol or terbutaline inhibited pentagastrin-stimulated acid secretion to a significantly greater extent than they inhibited bethanechol- or histamine-stimulated acid secretion. For example, isoproterenol (12 μg.kg-1.h-1) reduced mean pentagastrin-, bethanechol-, and histamine-stimulated acid output by 86, 63, and 14%, respectively. Percent inhibition of acid secretion with terbutaline (30 μg.kg-1.h-1) averaged 60, 17, and 24% for pentagastrin, bethanechol, and histamine, respectively. Terbutaline also inhibited pentagastrin-stimulated acid secretion from vagally denervated fundic pouches in a dose-related manner. Plasma somatostatin-like immunoreactivity was significantly higher during infusion of terbutaline plus pentagastrin than during infusion of pentagastrin alone. However, an intravenous infusion of 0.3 μg.kg-1.h-1 somatostatin-14 had no effect on pentagastrin-stimulated acid secretion from the gastric fistula, even though this infusion increased plasma somatostatin-like immunoreactivity to the same extent as terbutaline plus pentagastrin infusion. Thus the amount of somatostatin released during terbutaline infusion was not sufficient to explain the inhibition of pentagastrin-stimulated acid secretion observed.

UR - http://www.scopus.com/inward/record.url?scp=0022999925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022999925&partnerID=8YFLogxK

M3 - Article

C2 - 2876645

AN - SCOPUS:0022999925

VL - 251

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 4

ER -